Objective: The goal of this study was to compare the effects of 2 doses of pioglitazone hydrochloride (a thiazolidinedione insulin sensitizer) with placebo on glycated hemoglobin (HbAlc), insulin sensitivity, and lipid profiles in patients with type 2 diabetes mellitus who had suboptimal glycemic control and mild dyslipidemia.
INTRODUCTION
Type 2 diabetes mellitus carries risks for multiple complications, including microvascu]ar (eg, retinopathy, nephropathy, neuropathy) and macrovascular disease (eg, coronary heart disease, stroke, peripheral vascular disease). 1-3 Maintaining adequate glycemic control is an important therapeutic goal for lowering the risk of microvascular complications in patients with type 2 diabetes mellitus.1 An increased risk of cardiovascular disease often predates the onset of type 2 diabetes mellitus, 4 suggesting that reduction of cardiovascular risk may require an early and aggressive treatment strategy to promote lipid homeostasis (ie, reducing triglycerides [TGs] and increasing high-density lipoprotein cholesterol [HDL-C]) and improve glycemic control.
Insulin resistance with compensatory hyperinsulinemia is a defining feature of type 2 diabetes mellitus and an independent risk factor for coronary heart disease. 5, 6 Pharmacotherapy that increases insulin sensitivity has been shown to improve both glycemic and lipid profiles] Pioglitazone, a thiazolidinedione insulin sensitizer, has been shown in clinical studies to reduce glycated hemoglobin (HbAI,.), TGs, and free fatty acids while enhancing insulin sensitivity and elevating HDL-C. 8-1° Moreover, a recent study 11 has shown that pioglitazone reduces the atherogenic index of plasma (AIP), 12 an indicator of risk for cardiovascular disease. Thiazolidinediones are thought to produce beneficial effects on glucose and lipid levels through activation of peroxisome proliferator-activated receptor gamma, which is involved in transcriptional regulation of genes related to glucose homeostasis and lipid metabolism. 7 The goal of the present study was to compare pioglitazone 30 and 45 mg with placebo in controlling hyperglycemia and dyslipidemia in patients with recently diagnosed type 2 diabetes mellitus who had not been treated with insulin or oral antihyperglycemic medications (OAMs). The patient population under study had suboptimal glycemic control and mild dyslipidemia at baseline. In the present study, we also analyzed response rates to American Diabetes Association (ADA) criteria for glycemic control (HbAlc) and lipid levels (HDL-C and TGs). 13 Our findings add to the results of previous clinical trials of pioglitazone monotherapy in which pioglitazone improved fasting plasma glucose (EPG), HbAk, insulin sensitivity, and lipid profiles in patients with type 2 diabetes mellitus of longer duration, less satisfactory glycemic control, and more severe dyslipidemia. >,15
PATIENTS AND METHODS

Study Design
This was a randomized, double-blind, placebo-controlled, parallel-group study involving patients at 41 centers in Canada and Spain. The study consisted of 2 periods: a lead-in period in which all patients received placebo QD for 3 to 5 weeks, and a treatment period in which eligible patients were randomized to receive placebo, pioglitazone 30 mg QD, or pioglitazone 45 mg QD orally for 16 weeks. Patients were asked to maintain a consistent diet and exercise regimen throughout the study. Patients recorded their self-monitored blood glucose (SMBG) levels, hypoglycemic episodes, adverse events, and concomitant medications in a study diary. Each patient provided written informed consent for participation in the study. Eli Lilly and Company (Indianapolis, Indiana) sponsored the study and performed site monitoring and data collection and analysis.
Study conduct was approved by the institutional review board at each center, and the study was conducted in compliance with Good Clinical Practices and in accordance with the principles of the Declaration of Helsinki as amended in 1996.
Inclusion and Exclusion Crtter/a
There were 2 major inclusion criteria: (1) diagnosis of type 2 diabetes mellitus that was not controlled by diet and exercise and (2) no previous treatment with insulin or OAMs. At screening, HbAlc values for eligible patients were _>6.5% and <9.8%, generally indicative of mild to moderate hyperglycemia in type 2 diabetes mellitus.
Patients were excluded from the study for the following reasons: cardiac disease with marked limitation of functional capacity (New York Heart Association class III or IV clinical status); serum TGs >500 mg/dL (5.6 mmol/L) or total cholesterol (TC) >300 mg/dL (7.8 mmol/L); serum creatinine _>1.8 mg/dL (0.16 mmol/L); renal transplant or current renal dialysis; serum alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >2.5 times the upper limit of normal for the central laboratory; clinical signs or symptoms of liver disease; hemoglobin or hematocrit below the lower limit of normal for the central laboratory; previous HIV infection; treatment with systemic glucocorticoids (excluding topical and inhaled preparations) within the previous 4 weeks; body mass index (BMI) <25 kg/m2; signs or symptoms of substance abuse; or life expectancy <3 years.
Patients were allowed to use concomitant medications as required, except for insulin, other OAMs, systemic glucocorticoids (excluding topical and inhaled preparations), or nicotinic acid. Patients receiving lipoprotein-altering agents before enrollment were required to remain on the same dose for the duration of the study.
Laboratory and Safety Measurements
A central laboratory (Covance Laboratories, Indianapolis, Indiana) was used for analyses of all laboratory samples. FPG was measured using the hexokinase enzymatic method on Hitachi 747-200 chemistry analyzers (Roche Diagnostics, Indianapolis). HbAlc levels were measured from whole-blood samples by ionexchange high-performance liquid chromatography (Bio-Rad Variant analyzer, Bio-Rad Laboratories, Hercules, California). This system is certified by the National Glycohemoglobin Standardization Program to be traceable to the Diabetes Control and Complications Trial 16 reference method and values. The limits of detection were 3.6% to 17.8% (inclusive). The upper limit of the normal range was 6.1%. Intra-assay and interassay coefficients of correlation were 1.2% and 1.6%, respectively. Fasting serum insulin (FSI) levels were measured with the Microparticle Enzyme Immunoassay technique (Abbott Laboratories, Abbott Park, Illinois). The lipoprotein panel was performed with serum samples in accordance with the National Heart, Lung, and Blood Institute Lipid Standardi7ation Program. TC and TGs were measured photometrically using Hitachi analyzers. HDL-C was measured by dextran sulfate precipitation followed by assay of cholesterol on Hitachi analyzers. Low-density lipoprotein cholesterol (LDL-C) was measured directly by micellary solubilization followed by enzymatic assay on Hitachi analyzers. Assay of serum apolipoprotein B (apo B) was performed with the IMMAGE Immunochemistry System (Beckman Coulter, Inc., Palo Alto, California). The Homeostasis Model Assessment of Insulin Sensitivity (HOMA-S) was also used. Values of HOMA-S were derived from fasting insulin and FPG using a computer program from the Diabetes Research Laboratories (Oxford, United Kingdom). lr AlP was calculated as logl0(TGs/HDL-C), as previously described.11 Urine creatinine was measured using a Hitachi 911 analyzer.
Safety assessments consisted of adverse-event reporting as follows: hypoglycemic episodes; vital sign measurements, including changes in body weight; and laboratory abnormalities, with particular attention to hemoglobin, hematocrit, and serum ALl and AST. Hypoglycemic episodes were defined by either of the following: (1) a sign or symptom of hypoglycemia recorded in the patient diary, or (2) an SMBG of <50 mg/dL, regardless of the presence of hypoglycemic signs or symptoms. Adverse events were coded using a modified MedDRA dictionary.
Statistical Analysis
Descriptive statistics were used to summarize baseline characteristics for all patients. The primary time point for efficacy analyses was the study end point, defined as the last double-blind visit at which data were collected. For patients who completed the study, the end point took place after 16 weeks of treatment with study medication. Unless otherwise indicated, data are reported for the intent-totreat (ITT) population--all randomized patients who received _>1 dose of study medication and had both a baseline measurement and _>1 measurement of the dependent variable during the treatment period. Data describing least squares mean (LSM) changes from baseline to end point for HbAlc and HOMA-S are expressed as percent absolute units. Continuous efficacy variables were assessed by a fixedeffects analysis of covariance (ANCOVA), performed as a last observation carried forward analysis in which missing values for postbaseline measurements were imputed from the previous nonmissing postbaseline measurement for that variable. The ANCOVA model included treatment, investigator, and baseline value of the dependent variable as covariates. The overall test for treatment effect was performed with a significance level of P _< 0.05. Pairwise t tests between pioglitazone and placebo were calculated from LSM values derived from the model and were adjusted for multiplicity using Hochberg's method. 18 Differences among treatments for additional categorical variables were analyzed using chi-square tests.
We conducted 3 exploratory analyses in this study. First, treatment effects on HbAlc values were measured in patients stratified by baseline HbAlc as follows: low (_>6.5% to <7%); medium (_>7% to <8%); and high (_>8% to _<9.8%). Second, the proportion of patients achieving ADA target goals was assessed within these baseline strata. Third, we measured the proportion of patients meeting ADA target goals for TGs and HDL-C at baseline and end point. The overall level of significance of P _< 0.05 was maintained within each analysis using Hochberg's adjustment for multiplicity. 18
RESULTS
Patient Characteristics
A total of 297 patients were randomized to receive placebo, pioglitazone 30 mg QD, or pioglitazone 45 mg QD (n = 99 in each group). No significant differences in baseline characteristics were found between the 3 treatment groups ( Table I) . The majority of patients were white, with a mean (SD) age of 58.4 (10.9) years (range, 24-85 years) and mean (SD) BMI of 31.4 (4.8) kg/m 2. The mean (SD) duration of type 2 diabetes mellitus was 20.0 (37.4) months, and 30.6% of patients were receiving medication for dyslipidemia. Of the 297 patients randomized to receive treatment, 272 (91.6%) completed the study. A similar proportion of patients in each treatment group completed the study (88, 92, and 92 patients in the placebo, pioglitazone 30-mg, and pioglitazone 45-mg groups, respectively). In the placebo, pioglitazone 30-mg, and pioglitazone 45-mg groups, respectively, 5, 1, and 0 patients discontinued therapy due to lack of efficacy (as perceived by the physician and/or the patient); 1, 2, and 2 discontinued due to adverse events; 0, 4, and 1 were lost to follow-up; 1, 0, and 2 discontinued due to patient decision; 1, 0, and 1 did not meet the protocol entry criteria; 2, 0, and 0 violated the protocol; 0, 0, and 1 were discontinued due to the sponsor's decision; and 1, 0, and 0 were discontinued due to the physician's decision.
Glycemic Control and Insulin Sensitivity
As shown in Figure 1 , baseline mean HbA]~ values were 7.5%, 7.5%, and 7.6% for placebo, pioglitazone 30 mg, and pioglitazone 45 mg, respectively. HbAlc was reduced in the placebo group by 0.2% from baseline (P = 0.025). Treatment with pioglitazone 30 and 45 mg for 16 weeks reduced mean HbAlc by 0.8% and 0.9% from baseline, respectively (both P < 0.001 vs baseline and placebo). Subgroup analysis was conducted to examine the effect of pioglitazone in patients stratified by baseline HbAlc. Both doses of pioglitazone significantly reduced HbAlc levels at end point in patients with medium (>7% to <8%) or high (_>8% to _<9.8%) baseline HbAlc (both doses P < 0.001 vs placebo for both HbAlc categories; Figure 2 ). Mean reductions in HbA k for both doses were similar within these subgroups, ranging from 0.7% (medium, both doses) to 1.4% (high, 45-mg dose). In patients with low baseline HbAlc (>6.5% to <7%), pioglitazone 30 and 45 mg reduced end point values by 0.3% and 0.4%, respectively; HbAlc did not change in those patients who received placebo. However, in patients with low baseline HbAlc, changes in HbAlc did not differ significantly between the placebo group and the pioglitazone groups. baseline (31.4 pmol/L and 31.8 pmol/L, respectively); these changes were statistically significant compared with baseline (both P < 0.001) and placebo (P = 0.008 and P = 0.006, respectively). A reduction of 13.0 pmol/L was observed in the placebo group. In addition, pioglitazone 30 and 45 mg significantly increased HOMA-S values compared with baseline (both P < 0.001) and with placebo (P = 0.039 and P = 0.001, respectively); the LSM changes (minus the placebo values) were 13.9% and 20.0% for pioglitazone 30 and 45 mg, respectively.
Lipid Profile
Serum lipids were measured in all study patients at baseline and after 16 weeks of treatment with either placebo or pioglitazone (Figure 3) . Mean baseline levels of HDL-C were 1.20 mmol/L, 1.14 mmol/L, and 1.13 mmol/L for the placebo, pioglitazone 30-mg, and pioglitazone 45-mg groups, respectively. Pioglitazone 30 and 45 mg significantly increased levels of HDL-C from baseline (16% and 20%, respectively; both P < 0.001); this increase was significantly greater than that of the placebo group, which had an increase of 9% in HDL-C levels (P = 0.028 and P < 0.001, respectively). Mean baseline TGs were 1.72 mmol/L, 1.91 mmol/L, and 1.99 mmol/L for placebo, pioglitazone 30 mg, and pioglitazone 45 mg, respectively Although both pioglitazone 30 and 45 mg reduced TGs (5% and 16%, respectively), only the 45-mg dose produced a significant effect versus baseline and placebo (P < 0.001 and P = 0.007, respectively). Pioglitazone 45 mg pro- duced a small but significant reduction in apo B (5%; P = 0.020 vs baseline, P = 0.015 vs placebo, and P = 0.025 vs pioglitazone 30 mg), whereas pioglitazone 30 mg had no effect on this level. Pioglitazone 45 mg had no effect on TC and LDL-C. Pioglitazone 30 mg increased TC and LDL-C over baseline by 4% and 7%, respectively (P = 0.033 and P = 0.020). However, these changes were not significant compared with those of placebo.
Overall, the effects of pioglitazone were similar in the subset of patients currently receiving lipoprotein-altering medications (data not shown).
As shown in Figure 4 , pioglitazone 30 and 45 mg significantly reduced AIP (both P < 0.001 vs baseline; P = 0.018 and P < 0.001 vs placebo, respectively) and -FC:HDL-C ratio (both P < 0.001 vs baseline). In the 45-rag group, the decrease in TC:HDL-C ratio was significant compared with placebo (P = 0.005). Table IV shows the proportion of patients meeting ADA target goals for TGs and HDL-C at baseline and end point. In the ITT population, the proportion of patients reaching the target goal for TGs (<1.7 mmol/L) increased from 52.6% (50195) to 60.0% (57195) 
Safety Profile
Although the incidence of treatment-emergent adverse events was higher in patients treated with pioglitazone 45 mg compared with either pioglitazone 30 ther pioglitazone treatment group was statistically significantly different from placebo. The most frequently reported treatment-emergent adverse events (total incidence _>5%) were edema, nasopharyngitis, dizziness, back pain, headache, and arthralgia. Only the incidence of arthralgia was significantly different with pioglitazone 45 mg than with placebo (P : 0.017), at 2%, 3%, and 10% for placebo, pioglitazone 30 mg, and pioglitazone 45 mg, respectively. Serious adverse events (2% to 3% across groups) and discontinuations due to adverse events (1% to 2% across groups) were similar among the treatment groups. No statistically significant differences among the treatment groups were observed for incidences of hypoglycemic episodes--11%, 10%, and 11% for placebo, pioglitazone 30 rag, and pioglitazone 45 mg, respectively--or edema (coded as not otherwise specified, peripheral, and pitting edema)--16%, 14%, and 16% for placebo, pioglitazone 30 rag, and pioglitazone 45 mg, respectively. In general, adverse events were mild or moderate in severity. Body weight increased slightly in patients receiving pioglitazone (mean increase of 0.35 and 0.82 kg in the 30-and 45-mg groups, respectively; both P < 0.001 vs placebo); body weight decreased 1.58 kg in patients receiving placebo. Patients receiving pioglitazone 30 and 45 mg had slightly greater changes in hemoglobin (-3.4% and -4.9%, respectively, vs -0.7% with placebo; P = 0.001 and P < 0.001 vs placebo, respectively) and hematocrit (-0.6% and-2.1%, respectively, vs 1.2% with placebo; P = 0.004 and P < 0.001 vs placebo, respectively), but the investigators deemed these changes as not clinically meaningful. As shown in Table V , there were no significant differences in mean baseline serum ALT and AST values among treatment groups. Relative to baseline, serum ALT decreased in all groups and serum AST decreased in the pioglitazone-treated groups. Reductions in serum ALT for pioglitazone 30 mg and 45 mg were statistically significant versus placebo (P = 0.036 and P = 0.005, respectively). No treatment effect on urinary albumin/creatinine was observed in this study (data not shown).
DISCUSSION
The major finding of this large-scale, randomized, double-blind study was that administration of pioglitazone 30 or 45 mg for 16 weeks provided effective treatment for patients with type 2 diabetes mellitus with suboptimal glycemic control and mild dyslipidemia; our results support those of previous clinical trials of pioglitazone monotherapy. 14,15,19 The exclusion criteria used in the present study limit extrapolation to the general population. For example, individuals with a BMI <25 kg/m 2 were excluded from participation in the study, thereby eliminating lean patients whose level of insulin sensitivity and lipid profile may not match those of the overweight or obese patient with type 2 diabetes mellitus. However, examination of the characteristics of the patients included in this study suggests that these results may be applicable to the average patient with type 2 diabetes mellitus with suboptimal glycemic control. Pioglitazone reduced mean baseline HbAlc by 0.8% and 0.9% in the 30-and 45-mg groups, respectively (both P < 0.001 vs placebo). Both doses of pioglitazone reduced HbAlc by -1.4% in the subgroup with the highest baseline HbAlc (ranging from >8% to <9.8%) (both P < 0.001 vs placebo). These changes in patients with high baseline HbAlc were comparable to those observed previously 14 in patients who received piogfitazone monotherapy. In contrast, patients in the low-baseline subgroup (HbAlc >6.5% to <7%) showed only minimal (0.3% to 0.4%) reductions in HbAlc, suggesting that improvement in absolute HbAlc may depend on baseline levels. However, these reductions in HbAlc may prove clinically meaningful; longterm outcome studies indicate that even small reductions in HbAlc have been associated with improvements in the late stages of complications of diabetes.l,2
The results of the responder analysis were consistent with findings from the HbAlc analysis. In the ITT population, more patients in the pioglitazone 30-and 45-mg groups achieved the ADA target of HbAlc <7% than in the placebo group (P < 0.001 and P = 0.001 vs placebo, respectively). This benefit was most apparent in patients with high baseline HbAlc. Although 93.7% of pioglitazonetreated patients in the low-baseline subgroup of the ITT population (59/63) reached ADA target levels for HbAlc at end point, no definitive statement re-garding the benefit of pioglitazone for maintaining or achieving glycemic goals in patients with low-baseline disease can be made without further study.
The hyperinsulinemic euglycemic clamp technique is the gold standard for assessing insulin sensitivity. 2° However, this method is laborious and invasive, making it impractical to use in large-scale studies. In the present study, we used FSI and HOMA-S as indices of insulin sensitivity. Estimates of insulin sensitivity using HOMA-S have been shown to correlate strongly with estimates obtained by euglycemic clamp-measured glucose disposal. 21,22 The HOMA-S method is a simpler alternative to the euglycemic insulin clamp and provides an acceptable index of insulin sensitivity in both diabetic and nondiabetic individuals. Relative to baseline, pioglitazone 30 and 45 mg lowered the LSM (SE) ESI (by 31.4 [4.9] and 31.8 [4.8] pmol/L, respectively; both P < 0.001) and increased the LSM (SE) HOMA-S value (by 21.2% [4.6%] and 27.3% [4.5%], respectively; both P < 0.001), suggesting that both doses improved insulin sensitivity while reducing FPG. The 2 doses of pioglitazone were not significantly different from one another on measures of insulin sensitivity. Although this finding suggests that the 30-mg dose may be optimal for enhancing insulin sensitivity, Miyazaki et a119 have shown that pioglitazone dose-dependently improves whole-body and hepatic insulin sensitivity within a dose range of 7.5 to 45 mg.
The risk of coronary heart disease in patients with type 2 diabetes mellitus is 2-to 4-fold higher than that in those without diabetes. 5 Furthermore, cardiovascular complications account for 50% to 75% of deaths in patients with the disease, 23,24 underscoring the need for treatments that ameliorate cardiovascular risk in this population. Together with obesity and hypertension, dyslipidemia is a major cardiovascular risk factor in patients with type 2 diabetes mellitus and often precedes the onset of clinical disease. 25-27 In patients with type 2 diabetes mellitus, dyslipidemia often consists of elevated TGs, decreased HDL-C, and reduced LDL particle size, whereas TC and LDL may or may not be in the normal range. 5, 28 In the present study, pioglitazone 30 and 45 mg increased HDL-C compared with placebo (P = 0.028 and P < 0.001, respectively) and had no treatment effect on TC or LDL-C.
These data confirm results from previous studies 14,15 of pioglitazone monotherapy in patients with type 2 diabetes mellitus. Although the previous studies detected significant reductions from baseline in serum TGs after treatment with pioglitazone 30 mg, the present data found no significant difference in TGs with the 30-mg dose, but significant differences from baseline and placebo suggest that the 45-rag dose may benefit patients with elevated TGs (P < 0.001 vs baseline and P = 0.007 vs placebo).
We detected a significant reduction in apo B after treatment with pioglitazone 45 mg (P = 0.02 vs baseline; P = 0.025 vs pioglitazone 30 rag; P = 0.015 vs placebo). Two large studies 29,3° in the general population have shown that ele-vated apo B is a good predictor of ischemic heart disease and fatal myocardial infarctions. Thus, the possible dose dependency of this finding warrants further investigation in persons with type 2 diabetes mellitus. In addition, pioglitazone 30 and 45 mg significantly reduced AIP (both P < 0.001 vs baseline; P = 0.018 and P < 0.001 vs placebo, respectively), which has been shown to inversely correlate with LDL particle size.ll Small, dense LDL is associated with an increased risk of coronary artery disease. 3k32 The reduction in AlP observed in the present study implies a possible increase in LDL particle size, suggesting a reduction of the atherogenicity of LDL particles. Taken together, our data add to the results of previous studies >'~5 showing that monotherapy with pioglitazone improves lipid profiles associated with cardiovascular disease in patients with type 2 diabetes mellitus. Such effects may be specific to pioglitazone rather than the thiazolidinedione class as a whole; treatment with another thiazolidinedione, rosigfitazone, has been shown to increase TC, TGs, and LDL-C. [33] [34] [35] In the present study, the proportion of patients achieving ADA target goals for HDL-C increased after treatment with pioglitazone 30 and 45 mg (statistical significance not assessed), and the proportion of those receiving the 45-mg dose achieving ADA target goals for TGs also increased (statistical significance not assessed), further supporting a role for pioglitazone in ameliorating cardiovascular risk factors.
In the present study, pioglitazone 30 and 45 mg provided comparable improvements in glycemic control and insulin sensitivity These findings contrast with those of Aronoff et al, 14 who observed that 26-week treatment of OAM-naive patients with pioglitazone 45 mg lowered HbAlc by 2.6% relative to placebo, whereas pioglitazone 30 mg lowered HbA k. by only 1.3% (P < 0.05). However, compared with the present study, baseline HbAI~. values were 9.3% and 10.0% in the pioglitazone 30-and 45-mg groups, respectively, suggesting poorer glycemic control at baseline in their study Our results suggest that pioglitazone 45 mg improves dyslipidemia more than the 30-mg dose. Thus, it is possible that higher doses of pioglitazone are required to achieve maximal effects on dyslipidemia than those required for optimal glycemic control.
Treatment with pioglitazone was well tolerated. Whereas placebo-treated patients experienced mild weight loss, pioglitazone-treated patients experienced mild weight gain. Although the cause of weight loss in the placebo group is not clear, it may have resulted from continued glycosuria as a consequence of poor glycemic control or from ongoing improvements in diet and lifestyle. Assessment of potential risks associated with the modest weight gain commonly observed during pioglitazone therapy awaits long-term morbidity and mortality studies. However, several studies 36-3s have demonstrated that treatment with thiazolidinediones leads to an increase in subcutaneous fat accompanied by a decrease in visceral fat. Recently, Miyazaki et aP 8 suggested that the redistribution of body fat during pioglitazone therapy is associated with improved insulin sensitivity. Treatment with pioglitazone 30 and 45 mg was associated with nonclinically relevant decreases in hemoglobin and hematocrit, as well as with reductions in ALT (both P < 0.001 vs baseline; P = 0.036 and P = 0.005 vs placebo, respectively) and AST (P = 0.004 and P = 0.001 vs baseline, respectively; both P = NS vs placebo). Patients with type 2 diabetes mellitus have a high background prevalence of liver disease, including nonalcoholic steatohepatitis and fatty liver, 39,4° which have been associated with insulin resistance. 41,42 Although the clinical relevance of this finding is unknown, decreased serum aminotransferases after pioglitazone therapy may be associated with a reduction in hepatic steatosis as a result of improved insulin sensitivity Further studies will be necessary to investigate this possibility.
CONCLUSIONS
In this randomized, double-blind, placebo-controlled, multicenter study, pioglitazone 30 and 45 mg was administered to OAM-naive patients with type 2 diabetes mellitus with suboptimal glycemic control and mild dyslipidemia. Both doses of pioglitazone significantly reduced HbAlc in the ITT population. Compared with patients receiving placebo, more patients in both pioglitazone groups with medium or high baseline HbA~c achieved the ADA glycemic goal (HbAlc <7%) at end point. Both doses of pioglitazone improved insulin sensitivity (as demonstrated by decreased FSI and increased HOMA-S) and had a beneficial effect on lipid profiles, resulting in an improvement in AIP. Maximal improvement in lipid profiles (increased HDL-C and decreased TGs and apo B) was observed with pioglitazone 45 mg. The beneficial effects of pioglitazone on glycemic control, insulin sensitivity, and dyslipidemia may reduce morbidity and mortality in patients with type 2 diabetes mellitus.
